Connect Biopharma Holdings Limited

Cash runway now expected to extend into at least 2025 as a result of revised timeline of global Phase 3 program of…
Read More...

SAN DIEGO and TAICANG, SUZHOU, China, Dec. 02, 2022 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq:…
Read More...

– Company expects to report top-line data from China pivotal trial for lead drug candidate CBP-201 in atopic dermatitis…
Read More...

— Connect to Evaluate Efficacy and Safety Data on 255 Patients Already Enrolled — — Expected Timing for Potential…
Read More...

SAN DIEGO, CA and TAICANG, SUZHOU, China, Nov. 19, 2021 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited…
Read More...

Primary endpoint met with all three CBP-201 arms achieving significant improvements Significant improvements also…
Read More...